



Fig. S5. Distribution of horizontal visual analogue values of signs of the 5-aminolevulinic acid photodynamic therapy (ALA-PDT) and clobetasol propionate groups before treatment, at the end of treatment (week 8), and 6 months after the end of treatment. The severity of clinical signs (hyperkeratosis, atrophy, sclerosis, and depigmentation) were each graded as: 0=absent, 1=mild, 2=moderate, or 3=severe. * $p < 0.05$.